多发性硬化症的脆弱性:一个范围审查
Nida' Al Worikat1, Farzan Molaei2, Anna Zanotto3
1Department of Occupational Therapy Education, School of Health Professions, University of Kansas Medical Center, Kansas City, KS, United States; Department of Occupational Therapy, School of Rehabilitation Science, The University of Jordan, Amman, Jordan.
Multiple sclerosis and related disorders
|November 9, 2024
概括
在多发性硬化症 (MS) 中,虚弱是常见的,影响了17-66%的患者,并且比一般人群更早出现. 这次回顾强调了脆弱性.
科学领域:
- 神经学 神经学
- 老年学是指老年学的学科.
- 康复科学 康复科学 康复科学
背景情况:
- 虚弱是一种与年龄相关的疾病,在神经系统疾病中越来越多地被认可.
- 多发性硬化症 (MS) 是一种慢性神经疾病,影响年轻和中年成人.
- 脆弱对MS患者的影响 (pwMS) 是一个新兴的研究领域.
研究的目的:
- 进行关于pwMS脆弱性的流行率,特征和临床结果的范围审查.
- 综合当前关于MS临床因素与脆弱性之间的关联的证据.
- 确定MS群体中脆弱性和不良结果之间的关系.
主要方法:
- 在主要数据库 (PubMed,Scopus,Embase等) 进行系统的文献搜索. 和临床试验登记册.
- 包括2000年至2024年间发表的研究,没有语言限制.
- 选和选择符合预先定义的标准的11项研究 (10篇原创文章,1篇会议论文).
主要成果:
- 在pwMS中,脆弱性非常普遍,在门诊患者中报告的病率为17%至66%.
- 与普通人群相比,PwMS的脆弱性更早出现,参与者的平均年龄在41.2至58.6岁之间.
- 更高的残疾,更长的疾病持续时间,进展性多发性硬化,步行能力下降,睡眠不佳,疲劳,生活质量下降,跌倒,医疗保健利用率增加和死亡率与MS的脆弱性有关.
结论:
- 虚弱是多发性硬化症患者中普遍存在和显著的临床问题.
- 早期识别和管理脆弱性对于改善pwMS的结果至关重要.
- 需要进一步的研究,以充分理解和解决MS的脆弱性.
相关概念视频
01:18Factors Affecting Illness
When a person's physical, emotional, intellectual, social development or spiritual functioning is compromised, this deviation from a healthy normal state is called illness. Illness creates stress that in turn harms individuals. Irritation, anger, denial, hopelessness, and fear are behavioral and emotional changes an individual experiences in the phases of illness. A variety of factors influence a person's health and well-being.
For instance, risk factors are connected to illness, disability,...
For instance, risk factors are connected to illness, disability,...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...